2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Marijuana Abuse
3
Neoplasms
2
Epilepsy
2
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Pancreatic Cancer Non-resectable
1
Pain
1
Opioid-Related Disorders
1
Neurodevelopmental Disorders
1
Multiple Sclerosis
1
Marijuana Use
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Interventions
Standard of Care
8
Surveys and Questionnaires
7
COVID-19 Vaccines
6
Blood Specimen Collection
6
BNT162 Vaccine
6
Specimen Handling
5
2019-nCoV Vaccine mRNA-1273
5
Hydroxychloroquine
4
Surgical Procedures, Operative
3
Practice Guidelines as Topic
3
tocilizumab
2
sotrovimab
2
sinovac COVID-19 vaccine
2
cilgavimab and tixagevimab drug combination
2
Sodium Chloride
2
Pandemic Preparedness
2
Data Collection
2
CVnCoV COVID-19 vaccine
2
COH04S1 COVID-19 vaccine
2
Azithromycin
2
selinexor
1
remdesivir
1
regorafenib
1
proxalutamide
1
palbociclib
1
ogalvibart
1
monalizumab
1
lenzilumab
1
heterologous prime boost COVID-19 vaccination
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
COVID-19
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled